UK research information
Alluvi Retatrutide 40mg Pen: Product Information & UK Research
Learn about the Alluvi Retatrutide 40mg Pen, the science behind retatrutide, its UK regulatory status and the important differences between clinical research and commercially marketed products.
The Alluvi Retatrutide Pen is advertised by online sellers as a pre-filled pen containing 40mg of retatrutide. However, the label alone does not verify its ingredients, strength or quality.
UK status: Retatrutide is an investigational medicine. The Medicines and Healthcare products Regulatory Agency (MHRA) has not authorised it for use in the UK.
- Product Information
- Scientific Research
- UK Regulations
- FAQs
Shop Alluvi
Alluvi Retatrutide Pen: 20mg and 40mg Product Information
Online listings describe Alluvi-branded retatrutide pens in 20mg and 40mg presentations. These are advertised product labels, not independent confirmation of their contents, formulation or quality.
Alluvi Retatrutide 20mg Pen
Some sellers describe this product as a pre-filled pen containing 20mg of retatrutide. The advertised amount, product identity and sterility require independent verification.
£130.00
Alluvi Retatrutide 40mg Pen
The Alluvi Retatrutide 40mg Pen is marketed as a higher-strength presentation. Its label alone does not establish the actual amount of retatrutide or the quality of an individual pen.
£170.00
Product Information
What Is the Alluvi Retatrutide 40mg Pen?
The Alluvi Retatrutide 40mg Pen is a branded product presentation that online retailers describe as containing retatrutide, an investigational peptide developed by Eli Lilly.
It is important to distinguish the investigational molecule from an Alluvi-branded pen. Clinical studies establish findings about the medicine tested under controlled conditions, not the contents or safety of a third-party product.
| Detail | Information |
|---|---|
| Marketed product name | Alluvi Retatrutide 40mg Pen |
| Advertised presentation | Pre-filled pen |
| Advertised amount | 40mg |
| Claimed compound | Retatrutide |
| Compound development code | LY3437943 |
| Receptor activity | GLP-1, GIP and glucagon |
| UK regulatory status | Not authorised for use |
| Actual pen contents and sterility | Not independently verified |
Product presentation and amount reflect online seller descriptions. They should not be treated as independently verified specifications.
Scientific research
How Does Retatrutide Work?
Retatrutide is a triple-receptor agonist. Researchers study how its activity at three hormone receptors affects appetite, blood glucose and energy metabolism.
GLP-1 Receptor
GIP Receptor
Glucagon Receptor
Together, these three receptor activities form the basis of retatrutide's investigational approach. Researchers continue to evaluate its clinical benefits, risks and longer-term effects.
Clinical Research
What Does Clinical Research Show?
Eli Lilly is investigating retatrutide for obesity, type 2 diabetes and several related conditions through its clinical development programmes.
A Phase 2 trial published in The New England Journal of Medicine in 2023 reported a mean body-weight reduction of 24.2% after 48 weeks in the study group receiving the 12mg dose.
Lilly has since reported additional Phase 3 results. Researchers continue to assess the medicine’s safety and effectiveness across different patient groups.
“Important distinction: These findings relate to investigational retatrutide used in clinical trials. They do not demonstrate that an Alluvi-branded 40mg pen produces the same effects or meets pharmaceutical quality standards.”
Sources: Published Phase 2 Study · Eli Lilly Retatrutide Research
Verification
What Should You Know About Alluvi Pen Authenticity?
Packaging, branding and product descriptions cannot confirm what an injectable product contains.
When assessing claims about an Alluvi Retatrutide Pen, several questions matter:
- Product identity: Does independent testing confirm the claimed compound?
- Labelled amount: Does reliable batch-specific evidence support the stated 40mg quantity?
- Manufacturing source: Can the supplier identify and document the actual manufacturer?
- Batch traceability: Can the product be linked to authentic production and testing records?
- Sterility: Does appropriate evidence establish microbiological safety?
A Certificate of Analysis (COA) may provide analytical information, but its value depends on authenticity, testing methods and whether it genuinely relates to the product in question.
Chemical identity or purity testing alone cannot establish that a pen is safe for human injection.
UK regulations
Is Alluvi Retatrutide Legal in the UK?
The MHRA has not authorised retatrutide for use in the United Kingdom.
Retatrutide remains an investigational medicine, and the MHRA warns that products sold outside legitimate clinical trials may contain incorrect ingredients, inaccurate quantities or harmful contaminants.
The regulator also prohibits unauthorised consumer marketing of medicines that lack the required UK marketing authorisation.
Why UK Safety Warnings Matter
In October 2025, the MHRA announced a major seizure of unlicensed retatrutide and tirzepatide pens at a facility in Northampton.
A subsequent investigation by The Guardian reported that Alluvi branding appeared on seized products and examined allegations of continued unauthorised sales.
These findings raise important questions about product authenticity and supply. They do not establish that every product carrying the Alluvi name has the same origin.
Read the official MHRA safety guidance and the Guardian investigation.
Frequently Asked Questions about Alluvi Retatrutide Pen
What is the Alluvi Retatrutide Pen?
It is a branded pen product advertised by online sellers as containing retatrutide. Its actual ingredients, quantity and manufacturing quality require independent verification.
What does 40mg mean on an Alluvi Retatrutide Pen?
Is Alluvi Retatrutide the same as Eli Lilly's retatrutide?
Is retatrutide approved in the UK?
Is the Alluvi Retatrutide 40mg Pen safe to use?
Can I follow online instructions for using an Alluvi Retatrutide Pen?
Where can I find reliable information about retatrutide?
Research Sources & Further Reading
About Alluvi Retatrutide Pen
AlluviRetatrutidePen.co.uk provides information about the Alluvi Retatrutide Pen, published research and relevant UK regulatory developments.
Our content separates scientific evidence from unverified commercial product claims. We aim to help readers understand the available information without overstating what researchers or regulators have established.
Medical disclaimer: This website provides general information, not medical advice. It does not recommend the purchase, administration or use of unauthorised medicines. Consult a qualified healthcare professional about medical concerns or treatment decisions.